AstraZeneca plc (AZN) Earns Neutral Rating from JP Morgan Chase & Co

Author

27 July, 2017

The stock had a trading volume of 4,116,151 shares. The company has market cap of 25.05 billion Euro. The stock increased 0.28% or $0.2 during the last trading session, reaching $72.05.

About 241,792 shares traded.

AstraZeneca PLC is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. Next quarter's EPS is expected be $0.44 and the next full year EPS is projected to be $1.90. AstraZeneca plc has a one year low of $25.55 and a one year high of $35.60. The stock rose 0.44% or $0.15 reaching $33.95. About 159,922 shares traded. It has outperformed by 2.75% the S&P500. Therefore 100% are positive. BidaskClub lowered shares of AstraZeneca plc from a buy rating to a hold rating in a research report on Tuesday, July 11th. HSBC Holdings plc restated a "reduce" rating and set a GBX 4,200 ($54.84) price objective on shares of AstraZeneca plc in a report on Friday, May 5th. Cantor Fitzgerald maintained the stock with "Buy" rating in Friday, February 10 report. On Thursday, May 26 the stock rating was reinitiated by Janney Capital with "Neutral". Bernstein upgraded it to "Outperform" rating and €92 target in Tuesday, April 19 report.

Barclays PLC reiterated their overweight rating on shares of AstraZeneca plc (NYSE:AZN) in a research note released on Thursday, July 13th.

On May 15 the company was upgraded from "Underperform" to "Neutral" in a statement from Credit Suisse. The firm earned "Hold" rating on Monday, August 8 by Jefferies.

Analysts await AstraZeneca plc (ADR) (NYSE:AZN) to report earnings on July, 27 before the open. AZN's profit would be $1.08B giving it 19.19 P/E if the $0.44 EPS is correct. Equities research analysts anticipate that AstraZeneca plc will post $1.85 EPS for the current year. AstraZeneca plc (ADR) (NYSE:AZN) has risen 19.45% since July 26, 2016 and is uptrending. Investorplace.com's article titled: "AstraZeneca plc (ADR) (AZN) Shares Soar on Lung Cancer Drug Success" and published on May 12, 2017 is yet another important article. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the stock. Therefore 0 are positive. Colgate-Palmolive had 42 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has "Outperform" rating by Leerink Swann on Friday, December 9. BMO Capital Markets maintained Descartes Systems Group Inc (USA) (NASDAQ:DSGX) rating on Wednesday, May 31. The firm has "Overweight" rating by Piperjaffray given on Friday, September 23. The firm has "Buy" rating by Citigroup given on Thursday, April 14. The rating was downgraded by Barclays Capital on Monday, June 20 to "Underweight". Mutual Of America Capital Mgmt Limited Liability Company invested 0.06% in Centurylink Inc (NYSE:CTL). UBS has "Neutral" rating and $76 target. The company was upgraded on Friday, July 31 by Swedbank. Cleararc Capital holds 13,293 shares. The stock has "Market Perform" rating by Wells Fargo on Tuesday, November 15.

Investors sentiment decreased to 0.86 in 2016 Q4. Its down 0.28, from 1.14 in 2016Q3. It dived, as 69 investors sold CTL shares while 197 reduced holdings. 616.46 million shares or 0.02% less from 616.56 million shares in 2016Q3 were reported. Ronald Blue And Limited Liability Co has 3,464 shares. Westpac Bk holds 0% or 34,493 shares. Paloma Prns Mgmt owns 126,024 shares.

Foster & Motley Inc, which manages about $913.18 million and $522.55 million US Long portfolio, upped its stake in Schwab U.S. Reit Etf (SCHH) by 116,532 shares to 185,427 shares, valued at $7.61 million in 2016Q4, according to the filing.


More news